Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Kidney Function Decline in Patients with CKD and Untreated Hepatitis C Infection.

Tartof SY, Hsu JW, Wei R, Rubenstein KB, Hu H, Arduino JM, Horberg M, Derose SF, Qian L, Rodriguez CV.

Clin J Am Soc Nephrol. 2018 Oct 8;13(10):1471-1478. doi: 10.2215/CJN.01530218. Epub 2018 Sep 21.

PMID:
30242027
2.

Effectiveness, treatment completion and safety of sofosbuvir/ledipasvir and paritaprevir/ritonavir/ombitasvir + dasabuvir in patients with chronic kidney disease: an ERCHIVES study.

Butt AA, Ren Y, Puenpatom A, Arduino JM, Kumar R, Abou-Samra AB.

Aliment Pharmacol Ther. 2018 Jul;48(1):35-43. doi: 10.1111/apt.14799. Epub 2018 May 24.

PMID:
29797514
3.

HCV treatment initiation in persons with chronic kidney disease in the directly acting antiviral agents era: Results from ERCHIVES.

Butt AA, Ren Y, Puenpatom A, Arduino JM, Kumar R, Abou-Samra AB.

Liver Int. 2018 Aug;38(8):1411-1417. doi: 10.1111/liv.13672. Epub 2018 Jan 19.

PMID:
29271562
4.

Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial.

Bruchfeld A, Roth D, Martin P, Nelson DR, Pol S, LondoƱo MC, Monsour H Jr, Silva M, Hwang P, Arduino JM, Robertson M, Nguyen BY, Wahl J, Barr E, Greaves W.

Lancet Gastroenterol Hepatol. 2017 Aug;2(8):585-594. doi: 10.1016/S2468-1253(17)30116-4. Epub 2017 May 30.

PMID:
28576451
5.

Impact of Renal Disease on Patients with Hepatitis C: A Retrospective Analysis of Disease Burden, Clinical Outcomes, and Health Care Utilization and Cost.

Solid CA, Peter SA, Natwick T, Guo H, Collins AJ, Arduino JM.

Nephron. 2017;136(2):54-61. doi: 10.1159/000454684. Epub 2017 Feb 18.

PMID:
28214902
6.

Staphylococcus aureus infections following knee and hip prosthesis insertion procedures.

Arduino JM, Kaye KS, Reed SD, Peter SA, Sexton DJ, Chen LF, Hardy NC, Tong SY, Smugar SS, Fowler VG Jr, Anderson DJ.

Antimicrob Resist Infect Control. 2015 May 15;4:13. doi: 10.1186/s13756-015-0057-4. eCollection 2015.

7.

Naturally occurring IgG antibody levels to the Staphylococcus aureus protein IsdB in humans.

Zorman JK, Esser M, Raedler M, Kreiswirth BN, Ala'Aldeen DA, Kartsonis N, Smugar SS, Anderson AS, McNeely T, Arduino JM.

Hum Vaccin Immunother. 2013 Sep;9(9):1857-64. doi: 10.4161/hv.25253. Epub 2013 Jun 18.

8.

Distribution of hepatitis C virus genotypes in a diverse US integrated health care population.

Manos MM, Shvachko VA, Murphy RC, Arduino JM, Shire NJ.

J Med Virol. 2012 Nov;84(11):1744-50. doi: 10.1002/jmv.23399.

PMID:
22997077
9.

Epidemiology and outcome of major postoperative infections following cardiac surgery: risk factors and impact of pathogen type.

Chen LF, Arduino JM, Sheng S, Muhlbaier LH, Kanafani ZA, Harris AD, Fraser TG, Allen K, Corey GR, Fowler VG Jr.

Am J Infect Control. 2012 Dec;40(10):963-8. doi: 10.1016/j.ajic.2012.01.012. Epub 2012 May 19.

10.

Incidence and predictors of human papillomavirus-6, -11, -16, and -18 infection in young norwegian women.

Kim S, Arduino JM, Roberts CC, Marsico M, Liaw KL, Skjeldestad FE.

Sex Transm Dis. 2011 Jul;38(7):587-97. doi: 10.1097/OLQ.0b013e31820a9324.

PMID:
21301390
11.

Variation in the type and frequency of postoperative invasive Staphylococcus aureus infections according to type of surgical procedure.

Anderson DJ, Arduino JM, Reed SD, Sexton DJ, Kaye KS, Grussemeyer CA, Peter SA, Hardy C, Choi YI, Friedman JY, Fowler VG Jr.

Infect Control Hosp Epidemiol. 2010 Jul;31(7):701-9. doi: 10.1086/653205.

PMID:
20518637
12.

Incidence of and preoperative risk factors for Staphylococcus aureus bacteremia and chest wound infection after cardiac surgery.

Kanafani ZA, Arduino JM, Muhlbaier LH, Kaye KS, Allen KB, Carmeli Y, Corey GR, Cosgrove SE, Fraser TG, Harris AD, Karchmer AW, Lautenbach E, Rupp ME, Peterson ED, Straus WL, Fowler VG Jr.

Infect Control Hosp Epidemiol. 2009 Mar;30(3):242-8. doi: 10.1086/596015.

PMID:
19199534
13.

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.

Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, Frankel SR, Chen C, Ricker JL, Arduino JM, Duvic M.

J Clin Oncol. 2007 Jul 20;25(21):3109-15. Epub 2007 Jun 18.

PMID:
17577020
14.

Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A.

Marr KA, Hachem R, Papanicolaou G, Somani J, Arduino JM, Lipka CJ, Ngai AL, Kartsonis N, Chodakewitz J, Sable C.

Transpl Infect Dis. 2004 Sep;6(3):110-6.

PMID:
15569226
15.

Response to montelukast among subgroups of children aged 2 to 14 years with asthma.

Meyer KA, Arduino JM, Santanello NC, Knorr BA, Bisgaard H.

J Allergy Clin Immunol. 2003 Apr;111(4):757-62.

PMID:
12704354
16.

Assessment of markers of hepatitis C virus infection in a Japanese adult population.

Arduino JM, Stuver SO, Spiegelman D, Okayama A, Tabor E, Yu MW, Kohara M, Tsubouchi H, Mueller NE.

J Infect Dis. 2001 Nov 15;184(10):1229-35. Epub 2001 Oct 29.

PMID:
11679910
17.

Do HIV type 1 RNA levels provide additional prognostic value to CD4(+) T lymphocyte counts in patients with advanced HIV type 1 infection?

Arduino JM, Fischl MA, Stanley K, Collier AC, Spiegelman D.

AIDS Res Hum Retroviruses. 2001 Aug 10;17(12):1099-105.

PMID:
11522179
18.

Diffusive properties of immature articular cartilage.

Torzilli PA, Grande DA, Arduino JM.

J Biomed Mater Res. 1998 Apr;40(1):132-8.

PMID:
9511107
19.

Effect of proteoglycan removal on solute mobility in articular cartilage.

Torzilli PA, Arduino JM, Gregory JD, Bansal M.

J Biomech. 1997 Sep;30(9):895-902.

PMID:
9302612
20.

The predictive value of changes in serologic and cell markers of HIV activity for subsequent clinical outcome in patients with asymptomatic HIV disease treated with zidovudine.

Jacobson MA, De Gruttola V, Reddy M, Arduino JM, Strickland S, Reichman RC, Bartlett JA, Phair JP, Hirsch MS, Collier AC, et al.

AIDS. 1995 Jul;9(7):727-34.

PMID:
7546418
21.

Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. The NIAID AIDS Clinical Trials Group.

Fischl MA, Stanley K, Collier AC, Arduino JM, Stein DS, Feinberg JE, Allan JD, Goldsmith JC, Powderly WG.

Ann Intern Med. 1995 Jan 1;122(1):24-32.

PMID:
7985892
22.

Standardized microtiter assay for determination of syncytium-inducing phenotypes of clinical human immunodeficiency virus type 1 isolates.

Japour AJ, Fiscus SA, Arduino JM, Mayers DL, Reichelderfer PS, Kuritzkes DR.

J Clin Microbiol. 1994 Sep;32(9):2291-4.

23.

Serum p24 antigen level as an intermediate end point in clinical trials of zidovudine in people infected with human immunodeficiency virus type 1. Aids Clinical Trials Group Virology Laboratories.

DeGruttola V, Beckett LA, Coombs RW, Arduino JM, Balfour HH Jr, Rasheed S, Hollinger FB, Fischl MA, Volberding P.

J Infect Dis. 1994 Apr;169(4):713-21.

PMID:
8133085
24.

Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. The RV43 Study Group.

Mayers DL, Japour AJ, Arduino JM, Hammer SM, Reichman R, Wagner KF, Chung R, Lane J, Crumpacker CS, McLeod GX, et al.

Antimicrob Agents Chemother. 1994 Feb;38(2):307-14.

25.

Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group.

Japour AJ, Mayers DL, Johnson VA, Kuritzkes DR, Beckett LA, Arduino JM, Lane J, Black RJ, Reichelderfer PS, D'Aquila RT, et al.

Antimicrob Agents Chemother. 1993 May;37(5):1095-101.

26.

Supplemental Content

Loading ...
Support Center